Abstract:Background Progressive fibrosing interstitial lung disease (ILD) is characterised by parenchymal scar formation, leading to high morbidity and mortality. The ability to predict this phenotype remains elusive. We conducted a proteomic analysis to identify novel plasma biomarkers of progressive fibrosing ILD and developed a proteomic signature to predict this phenotype. Methods Relative plasma concentrations for 368 biomarkers were determined with use of a semi-quantitative, targeted proteomic platform in patients with connective tissue disease-associated ILD, chronic hypersensitivity pneumonitis, or unclassifiable ILD who provided research blood draws at the University of California (discovery cohort) and the University of Texas (validation cohort). Univariable logistic regression was used to identify individual biomarkers associated with 1-year ILD progression, defined as death, lung transplant, or 10% or greater relative forced vital capacity (FVC) decline. A proteomic signature of progressive fibrosing ILD was then derived with use of machine learning in the University of California cohort and validated in the University of Texas cohort. Findings The discovery cohort comprised 385 patients (mean age 63.6 years, 59% female) and the validation cohort comprised 204 patients (mean age 60.7 years, 61% female). 31 biomarkers were associated with progressive fibrosing ILD in the discovery cohort, with 17 maintaining an association in the validation cohort. Validated biomarkers showed a consistent association with progressive fibrosing ILD irrespective of ILD clinical diagnosis. A proteomic signature comprising 12 biomarkers was derived by machine learning and validated in the University of Texas cohort, in which it had a sensitivity of 0.90 and corresponding negative predictive value of 0.91, suggesting that approximately 10% of patients with a low-risk proteomic signature would experience ILD progression in the year after blood draw. Those with a low-risk proteomic signature experienced an FVC change of +85.7 mL (95% CI 6.9 to 164.4) and those with a high-risk signature experienced an FVC change of -227.1 mL (-286.7 to -167.5). A theoretical clinical trial restricted to patients with a high-risk proteomic signature would require 80% fewer patients than one designed without regard to proteomic signature. Interpretation 17 plasma biomarkers of progressive fibrosing ILD were identified and showed consistent associations across ILD subtypes. A proteomic signature of progressive fibrosing ILD could enrich clinical trial cohorts and avoid the need for antecedent progression when defining progressive fibrosing ILD for clinical trial enrolment. Copyright (C) 2022 Elsevier Ltd. All rights reserved.

Predictive Value of Flow Cytometry Quantification of BAL Lymphocytes and Neutrophils in ILD

Neutrophils and Lymphocytes: Yin and Yang of Lung Fibrosis and Patient Outcome in Diffuse Interstitial Lung Diseases

Bronchoalveolar Lavage Fluid Cellular Analysis and Radiologic Patterns in Patients with Fibrotic Interstitial Lung Disease

Diagnostic and prognostic biomarkers for progressive fibrosing interstitial lung disease

Interstitial lung disease: performance of neutrophil-lymphocyte ratio in predicting progression

Value of bronchoalveolar lavage fluid metagenomic next-generation sequencing in acute exacerbation of fibrosing interstitial lung disease: an individualized treatment protocol based on microbiological evidence

Predicting progressive phenotype in patients with fibrotic interstitial lung disease

Proteomic Biomarkers of Progressive Fibrosing Interstitial Lung Disease: a Multicentre Cohort Analysis.

Proteomic profiling of bronchoalveolar lavage fluid uncovers protein clusters linked to survival in idiopathic forms of interstitial lung disease

Mass cytometry identifies characteristic immune cell subsets in bronchoalveolar lavage fluid from interstitial lung diseases

Late Breaking Abstract - Developing a prognostic SLB-derived gene signature in fibrosing ILDs

BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases

S55 Derivation and Validation of a Simple Longitudinal Score Which Strongly Predicts Mortality in Interstitial Lung Disease (ild) Associated Pulmonary Hypertension (Ild-Ph)

Role of BAL and Serum Krebs von den Lungen-6 (KL-6) in Patients with Pulmonary Fibrosis

Exhaled breath condensate in ILD with ultrasensitive cytokine measurement: paving the way of a non-invasive investigational tool

Prognostic performance of Krebs von den Lungen-6, surfactant protein A, surfactant protein D levels in the serum and bronchoalveolar lavage fluid in chronic fibrosing interstitial pneumonia: a retrospective study

A meta-analysis of the clinical significance of neutrophil-to-lymphocyte ratios in interstitial lung disease

Development of a scoring system with multidimensional markers for fibrosing interstitial lung disease

Admission chest CT scan of intensive care patients with interstitial lung disease: Unveiling its limited predictive value through visual and automated analyses in a retrospective study (ILDICTO)

Diagnostic Performance of CLEIA Versus FEIA for KL‐6 Peripheral and Alveolar Concentrations in Fibrotic Interstitial Lung Diseases: A Multicentre Study

Blood eosinophilia: a predictive marker of acute exacerbations in fibrotic interstitial lung disease?